NCT06591273View on ClinicalTrials.gov

Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

104

Participants

Timeline

Start Date

November 6, 2023

Primary Completion Date

November 5, 2024

Study Completion Date

November 5, 2024

Conditions

Moderate to Severe Chronic Plaque Psoriasis

Interventions

BIOLOGICAL

Infliximab-dyyb Biosimilar (Remsima)

Subcutaneous injections of Infliximab-dyyb Biosimilar (Remsima) were injected weekly for 4 weeks and then fortnightly for 24 weeks

Trial Locations (1)

54000

Department of Dermatology, Services Institute of Medical Sciences/ Services Hospital, Lahore

All Listed Sponsors

lead

Services Institute of Medical Sciences, Pakistan

OTHER_GOV

NCT06591273 - Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial | Biotech Hunter | Biotech Hunter